Shopping Cart
- Remove All
- Your shopping cart is currently empty
TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It exhibits a concentration-dependent bronchodilatory effect mediated by released NO through a cGMP-dependent pathway. Studies suggest that TPI-1020 combines corticosteroid activity with NO release, potentially benefiting the treatment of acute bronchoconstriction events in asthma and allowing for a reduced dose of inhaled beta(2)-adrenoceptor agonists.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | TPI-1020 is a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide. It exhibits a concentration-dependent bronchodilatory effect mediated by released NO through a cGMP-dependent pathway. Studies suggest that TPI-1020 combines corticosteroid activity with NO release, potentially benefiting the treatment of acute bronchoconstriction events in asthma and allowing for a reduced dose of inhaled beta(2)-adrenoceptor agonists. |
Alias | TPI1020, TPI 1020, NCX-1020, NCX 1020 |
Molecular Weight | 609.66 |
Formula | C33H39NO10 |
Cas No. | 571186-52-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.